

Alzheimer's Disease Genetics Consortium

ADGC



Gerard D. Schellenberg, Ph.D.
Perelman School of Medicine
University of Pennsylvania




ADGC


Formed to do large-scale genetic studies on Alzheimer's disease

Goal: Identify all genes/inherited factors that increase risk or protect against Alzheimer's disease.

Alzheimer's Disease Center Samples



Alzheimer's Disease Center Samples



Other cohorts ACC

NCRAD Tatiana Foroud

phenotype data
genotype data
DNAphenotype
data

Lindsay Farrer
Jonathan Haines
Richard Mayeux
Peggy Pericak-Vance
Jerry Schellenberg

ADGC

genotypes
sequence

DNA

genetic studies → publish

NIAGADS
Li-San Wang

Return to ADCs

- DNA
- *APOE* genotypes
- Genome-wide SNP array data
- **Key SNP genotypes for risk-loci**
- Exome chip data
- Sequence data – exome/whole genome

- recognition

ADC Contribution

	Phase 1/MDS	Phase 2/UDS	Total
Total Submitted	3774	10550	14324
Illumina 660/Omni Express	2990	8405	11395
Exome Chip	2673	4418	7091

ADC Genotyping

Cohort	Cases	Controls	MCI	Other	Total
Received	8066	6450	1628	4466	20610
Genotyped	5873	4499	560	463	11395



Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

Eleven susceptibility loci for late-onset Alzheimer's disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer's disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer's disease cases and 11,312 controls. In addition to the *APOE* locus (encoding apolipoprotein E), 19 loci reached genome-wide significance ($P < 5 \times 10^{-8}$) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer's disease.

Jean-Charles Lambert^{1-3,145}, Carla A Ibrahim-Verbaas^{4,5,145}, Denise Harold^{6,145}, Adam C Naj^{7,8,145}, Rebecca Sims⁶, Céline Bellenguez¹⁻³, Gyungah Jun⁹⁻¹¹, Anita I DeStefano¹, Joshua C Bis¹², Gary W Beecham^{13,14}, Benjamin Grenier-Boley¹⁻³, Giancarlo Russo¹⁵, Tricia A Thornton-Wells¹⁶, Nicola Jones⁶, Albert V Smith^{17,18}, Vincent Chouraki¹⁻³, Charlene Thomas⁶, M Arfan Ikram^{4,5,19,20}, Diana Zelenika²¹, Badri N Vardarajan⁹, Yoichiro Kamatani²², Chiao-Feng Lin²³, Amy Gerrish⁶, Helena Schmidt²⁴, Brian Kunkle¹³, Melanie L Dunstan⁶, Agustin Ruiz²⁵, Marie-Thérèse Bihoreau²¹, Seung-Hoan Choi¹, Christiane Reitz^{26,27}, Florence Pasquier^{28,28}, Paul Hollingworth⁶, Alfredo Ramirez^{29,30}, Olivier Hanon³¹, Annette L Fitzpatrick^{12,32,33}, Joseph D Buxbaum³⁴⁻³⁶, Dominique Campion³⁷, Paul K Crane³⁸, Clinton Baldwin⁹, Tim Becker^{39,40}, Vilundur Gudnason^{17,18}, Carlos Cruchaga^{41,42}, David Craig⁴³, Najaf Amin⁵, Claudine Berr⁴⁴, Oscar L Lopez⁴⁵, Philip L De Jager^{46,47}, Vincent Deramecourt^{48,28}, Janet A Johnston⁴⁹, Denis Evans⁴⁸, Simon Lovestone⁴⁹, Luc Letenneur⁵⁰, Francisco J Morón⁵¹, David C Rubinsztein⁵², Gudny Eiriksdottir¹⁸, Kristel Slegers^{53,54}, Alison M Goate^{41,42}, Nathalie Fievet^{1,3}, Matthew J Huentelman⁵⁵, Michael Gill⁵⁶, Kristelle Brown⁵⁷, M Ilyas Kamboh^{58,59}, Lina Keller⁶⁰, Pascale Barberger-Gateau⁵⁰, Bernadette McGuinness⁴³, Eric B Larson^{38,61}, Robert Green⁶², Amanda J Myers⁶³, Carole Dufouil⁶⁰, Stephen Todd⁴³, David Wallon³⁷, Seth Love⁶⁴, Ekaterina Rogaeva⁶⁵, John Gallacher⁶⁶, Peter St George-Hyslop^{62,65,67}, Jordi Clarimon^{68,69}, Albert Lleo^{68,69}, Anthony Bayer⁶⁶, Debby W Tsuang⁷⁰, Lei Yu⁷¹, Magda Tzolaki⁷², Paola Bossù⁷³, Gianfranco Spalletta⁷³, Petroula Proitsi⁴⁹, John Collinge⁷⁴, Sandro Sorbi^{75,76}, Florentino Sanchez-Garcia⁷⁷, Nick C Fox⁷⁸, John Hardy^{79,80}, Maria Candida Deniz Naranjo⁷⁷, Paolo Bosco⁸¹, Robert Clarke⁸², Carol Brayne⁸³, Daniela Galimberti⁸⁴, Michelangelo Mancuso⁸⁵, Fiona Matthews⁸⁶, European Alzheimer's Disease Initiative (EADI)⁸⁷, Genetic and Environmental Risk in Alzheimer's Disease (GERAD)⁸⁷, Alzheimer's Disease Genetic Consortium (ADGC)⁸⁷, Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)⁸⁷, Susanne Moebus⁸⁸, Patrizia Mecocci⁸⁹, Maria Del Zompo⁹⁰, Wolfgang Maier^{29,39}, Harald Hampel^{91,92}, Alberto Pilotto⁹³, Maria Bullido⁹⁴⁻⁹⁶, Francesco Panza⁹⁷, Paolo Caffarra^{98,99}, Benedetta Nacmias^{75,76}, John R Gilbert^{13,14}, Manuel Mayhaus¹⁰⁰, Lars Lannfelt¹⁰¹, Hakon Hakonarson¹⁰², Sabrina Pichler¹⁰⁰, Minerva M Carrasquillo¹⁰³, Martin Ingelsson¹⁰¹, Duane Beekly¹⁰⁴, Victoria Alvarez¹⁰⁵, FANGGANG ZOU¹⁰³, Otto Valladares²³, Steven G Younkin¹⁰³, Eliczer Coto¹⁰⁵, Kara L Hamilton-Nelson¹³, Wei Gu¹⁰⁰, Cristina Razquin¹⁰⁶, Pau Pastor^{106,107}, Ignacio Mateo^{108,109}, Michael J Owen⁶, Kelley M Faber¹¹⁰, Palmi J Jonsson^{17,111}, Onofre Combarros^{108,109}, Michael C O'Donovan⁶, Laura B Cantwell⁶³, Hilkka Soininen^{112,113}, Deborah Blacker^{114,115}, Simon Mead⁷⁴, Thomas H Mosley Jr¹¹⁶, David A Bennett^{71,117}, Tamara B Harris¹², Laura Fratiglioni^{60,118}, Clive Holmes¹¹⁹, Renee F A G de Bruijn^{4,5,20}, Peter Passmore⁴³, Thomas J Montine¹²⁰, Karolien Bettens^{53,54}, Jerome I Rotter¹²¹, Alexis Brice^{122,123}, Kevin Morgan⁵⁷, Tatiana M Foroud¹¹⁰, Walter A Kukull²³, Didier Hannequin³⁷, John F Powell⁴⁹, Michael A Nalls¹²⁴, Karen Ritchie^{13,14}, Kathryn L Lunetta¹¹, John S K Kauwe¹²⁶, Eric Boerwinkle¹²⁷⁻¹²⁹, Matthias Riemschneider¹⁰⁰, Mercè Boada^{25,130}, Mikko Hiltunen^{112,113}, Eden R Martin^{13,14}, Reinhold Schmidt¹³¹, Dan Rujescu¹³², Li-San Wang²³, Jean-François Dartigues^{50,133}, Richard Mayeux^{26,27}, Christophe Tzourio¹³⁴, Albert Hofman^{5,20}, Markus M Nöthen¹³⁵, Caroleine Graff^{117,136}, Bruce M Psaty^{12,32,61,137}, Lesley Jones⁶, Jonathan L Haines^{16,138}, Peter A Holmans⁶, Mark Lathrop^{21,22,139}, Margaret A Pericak-Vance^{13,14}, Lenore J Launer¹⁴⁰, Lindsay A Farrer^{9-11,141,142}, Cornelia M van Duijn^{5,20,143}, Christine Van Broeckhoven^{53,54}, Valentina Moskvina⁶, Sudha Seshadri^{142,145,146}, Julie Williams^{6,145,146}, Gerard D Schellenberg^{23,145,146} & Philippe Amouyel^{1-3,28,144-146}

Published
2013/2014

Christiane Reitz *et al.*

ABCA7 and AD in African Americans.
JAMA **309**, 1483-1492. (2013)

Patrick Holton *et al.*

Pathogenic mechanisms of AD risk Loci.
Ann. Hum. Genet. **77**: 85-105.

Perry G. Ridge *et al.*

AD and missing heritability
PLoS One, Nov **7**;8(11):e79771.

Bruno A. Benitez *et al.*

TREML2 variants protects against AD.
Neurobiol. Aging 35 1510.e19e

Agustín Ruiz *et al.*

TRIP4 - a novel AD gene.
Translational Psychiatry **4**, e358.

Published
2013/2014
(cont).

Christiane Reitz *et al.*

VPS10-d receptor and AD loci

Transl. Psychiatry 14;3:e256. doi: 10.1038/tp.13

Christiane Reitz *et al.*

TREM2 Variants in AD – African Americans

New Engl. J. Med. **369**:1564

Akinori Miyashita *et al.*,

SORL1 in AD - Japanese, Koreans and Caucasians.

PLOS One **8**: 1-11, e58618.

Carlos Cruchaga *et al.*

GWAS of CSF tau/A β

Neuron **78**, 256-268

In press
2014

Valentina Escott-Price *et al.*

Gene-wide analysis - two new susceptibility genes for AD.
Plos One

Adam Naj *et al.*

Age-at-Onset Modified by Multiple Genetic Loci.
JAMA Neurol.

Peter Nelson *et al.*

ABCC9 and hippocampal sclerosis.
Acta Neuropathol.

Submitted
2014

Tom Montine, Gary Beecham:
Neuropathology trait GWAS

Li-San Wang
APP A673T, an AD protective variant in the US

4 other manuscripts

Ongoing Analyses

- Cognitive decline GWAS
- Exome chip - rare variants

Cohort	Cases	Controls	Total
GWAS 1	10,491	11,449	21,940
New samples	3,000	4,079	7,079
Totals	13,491	15,528	29,019

- Expanded common variant GWAS
- Rare variant GWAS

Alzheimer's Disease Sequencing Project (ADSP)

Whole-genome sequencing: 585 subjects from 111 multiplex families (multiple case/family)

Sequencing complete
Data quality being evaluated

Whole exome sequencing: 5,000 unrelated cases
5,000 unrelated elderly controls
1,000 cases – multiplex families
11,000 total

Sequencing 50% complete


Replication phase: 25,000 case
25,000 controls

ADSP Analyses

WGS:

- Family-based analyses – rare variants
- Structural variants
 - Insertion/deletions
 - Copy number variation
 - Inversions
 - Translocation

ADSP Analyses



Thank you!